Menlo Therapeutics Announces Addition of Ronald A. Krasnow as General Counsel and Chief Compliance Officer
“Ron brings over 20 years of experience as in-house legal counsel, with particular strength in intellectual property law. He has also overseen the legal activities related to a commercial drug launch, including compliance, market access contracting, and commercial supply agreements. His experience will be valuable to us as we prepare for the launch of serlopitant, if approved, for the treatment of pruritus associated with prurigo nodularis,” said
Most recently, Mr. Krasnow served as General Counsel, Chief Strategy Officer and Secretary at
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Menlo Therapeutics, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including, but not limited to, statements regarding ongoing clinical trials and the potential regulatory approval for serlopitant for pruritus associated with prurigo nodularis. Such forward-looking statements involve substantial risk and uncertainties that could cause Menlo Therapeutics’ development program for serlopitant, future financial results, achievements or performance to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks that clinical trials are unsuccessful, despite prior successfully completed clinical trials or do not demonstrate efficacy of serlopitant in the studied indications. These factors, together with those that are described in greater detail in Menlo Therapeutics’ Quarterly Report on Form 10-Q to filed on May 2, 2019, as well as any reports that it may file with the SEC in the future, may cause Menlo Therapeutics’ actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Menlo Therapeutics undertakes no obligation to update or revise any forward-looking statements.
Media Contact: firstname.lastname@example.org
Investor Contact: email@example.com
Source: Menlo Therapeutics Inc.